## Claims:

15

- A solid drug delivery composition comprising one or more NO-donating Non Steroidal Antiinflammatory Compound(s) (NO-donating NSAID(s)) absorbed into porous particles.
  - 2. The solid drug delivery composition according to claim 1 wherein one or more NO-donating NSAID(s) in oily form is absorbed into porous particles.
- 3. The solid drug delivery composition according to claim 1 wherein one or more NO-donating NSAID(s) in melted form is absorbed into porous particles.
  - 4. The solid drug delivery composition according to any one of claims 1 to 3 wherein the porous particles are selected from the group consisting of dibasic calcium phosphate:

    anhydrous, microcrystalline cellulose and pregelatinised starch or a mixture thereof.
  - 5. The solid drug delivery composition according to any one of claims 1 to 4 wherein the porous particles are spherical with a particle size between 50 and 500  $\mu m$ .
- 6 The solid drug delivery composition according to claim 5 wherein the particle size of the spherical porous particles is between 100 and 150 μm.
  - 7. The solid drug delivery composition according to any one of claims 1 to 4 wherein the pore size of the porous particles is between 10 and 1000 Å.
  - 8. The solid drug delivery composition according to claim 7 wherein the pore size of the porous particles is between 20 and 750 Å.
- 9. The solid drug delivery composition according to claim 8 wherein the pore size of the porous particles is between 50 and 500 Å.

15

- 10. The solid drug delivery composition according to any one of claims 1 to 9 wherein one or more NO-donating NSAID(s) is absorbed together with one or more surfactant(s) into the porous particles.
- 11. The solid drug delivery composition according to any one of claims 1 to 9 comprising a combinations of
  - a) porous particles comprising an NO-donating NSAID and one or more surfactant(s) and b) porous particles comprising an NO-donating NSAID without surfactant.
- 12. The solid drug delivery composition according to any one of claims 10 or 11 wherein the NO-donating NSAID(s) are the same.
  - 13. The solid drug delivery composition according to any one of claims 10 to 12 wherein the surfactant(s) is non-ionic.
  - 14. The solid drug delivery composition according to claim 13 wherein the surfactant(s) is a block co-polymer.
- 15. The solid drug delivery composition according to claim 13 wherein the surfactant(s) is a poloxamer.
  - 16. The solid drug delivery composition according to claim 13 wherein the surfactant(s) is a polyoxyethylene polyoxybutylene block copolymer.
- 17. The solid drug delivery composition according to any one of claims 10 to 16 wherein the ratio NO-donating NSAID(s):surfactant(s) is within the range from 1:0.1 to 1:10 (w/w).
  - 18. The solid drug delivery composition according to claim17 wherein the ratio NO-donating NSAID(s):surfactant(s) is within the range from 1:0.3 to 1:3 (w/w).
  - 19. The solid drug delivery composition according to any one of claims 1 to 18 wherein the NO-donating NSAID is an NO-donating naproxen.

10

20

25

- 20. The solid drug delivery composition according to claim 19 wherein the NO-donating naproxen is 4-(nitrooxy)butyl-(S)-2-(9-methoxy-2-naphtyl)-propanoate.
- 21. The solid drug delivery composition according to any one of claims 1 to 18 wherein the NO-donating NSAID is an NO-donating diclofenac.
  - 22. The solid drug delivery composition according to claim 21 wherein the NO-donating diclofenac is 2-[(2,6-dichlorophenyl)amino]benzeneacetic acid 4-(nitrooxy)-butyl ester.
  - 23. The solid drug delivery composition according to claim 21 wherein the NO-donating diclofenac is 2-[2-(nitrooxy)ethoxy]ethyl {2-[(2,6-dichlorophenyl)amino]phenyl}acetate.
- 24. The solid drug delivery composition according to any one of claims 1 to 18 wherein the NO-donating NSAID is an NO-donating ketoprofen.
  - 25. The solid drug delivery composition according to claim 24 wherein the NO-donating ketoprofen is 2-(3-benzoyl-phenyl)-propionic acid 3-nitrooxy-propyl ester or 2-(3-benzoyl-phenyl)-propionic acid 4-nitrooxymethyl-benzyl ester.
  - 26. The solid drug delivery composition according to any one of claims 1 to 25 wherein the porous particles comprising an NO-donating NSAID, optionally mixed with one or more surfactant(s), are mixed together with enteric coated pellets comprising a H<sup>+</sup>, K<sup>+</sup>-ATPase inhibitor.
  - 27. The solid drug delivery composition according to claim 26 wherein the porous particles comprising an NO-donating naproxen, an NO-donating diclofenac, an NO-donating ketoprofen or an NO-donating ketorolac, optionally mixed with one or more surfactant(s), are mixed together with enteric coated pellets comprising omeprazole, esomeprazole, lansoprazole, pantoprazole or rabeprazole, leminoprazole or a pharmaceutical acceptable salt thereof.

- 28. Process for producing the porous particles comprising one or more NO-donating NSAID(s) according to any one of claims 1 to 25 comprising mixing the NO-donating NSAID(s), optionally in oily or melted form, with porous particles.
- 29. Process for producing the porous particles comprising one or more NO-donating NSAID(s) according to any one of claims 1 to 25 comprising:
  - a) dissolving the NO-donating NSAID(s) in one or more alcohol(s),
  - b) adding the porous particles during stirring,
  - c) evaporating the added alcohol(s),
- d) recovering the porous particles comprising the NO-donating NSAID(s), with a) and b) in optional order.
  - 30. Process for producing the porous particles comprising one or more NO-donating NSAID(s) according to any one of claims 1 to 25 comprising:
- a) melting the NO-donating NSAID(s),
  - b) adding the porous particles,
  - c) stirring the obtained mixture,
  - d) recovering the porous particles comprising the NO-donating NSAID(s), with a) and b) in optional order.
  - 31. Process for producing porous particles comprising one or more NO-donating NSAID(s) and one or more surfactant(s) according to any one of claims 1 to 25 comprising:
  - a) mixing the NO-donating NSAID(s) and the surfactant(s),
  - b) adding the porous particles,
- 25 c) stirring the obtained mixture,
  - d) recovering the porous particles comprising the NO-donating NSAID(s) and the surfactant(s),
  - with a) and b) in optional order.
- 32. Process for producing the porous particles comprising one or more NO-donating NSAID(s) and one or more surfactant(s) according to any one of claims 1 to 25 comprising:

- a) melting NO-donating NSAID(s) and the surfactant(s),
- b) adding the porous particles,
- c) stirring the obtained mixture,
- d) recovering the porous particles comprising NO-donating NSAID(s) and the
- surfactant(s),

with a) and b) in optional order.

- 33. Process for producing the porous particles comprising one or more NO-donating NSAID(s) according to any one of claims 1 to 25 comprising:
- 10 a) mixing the NO-donating NSAID(s) and the porous excipient,
  - b) adding water, stepwise, continuously, in one portion,
  - c) extruding the obtained mixture into particles,
  - d) spheronising the obtained particles,
  - e) drying the obtained mixture,
- 15 f) recovering the porous particles comprising the NO-donating NSAID(s).
  - 34. The process according to claim 33 wherein the NO-donating NSAID(s) in step a) is pre-heated.
- 35. The process according to any one of claims 28 to 34 wherein the NO-donating NSAID(s) are the same.
  - 36. The solid drug delivery composition comprising the porous particles according to any one of claims 1 to 25 wherein the porous particles have been produced according to any one of claims 28 to 35, are mixed with pharmaceutically acceptable excipients and compressed into a tablet.
  - 37. The solid drug delivery composition comprising the porous particles according to any one of claims 1 to 25 wherein the porous particles have been produced according to any one of claims 28 to 35, are filled into a capsule.

- 38. The solid drug delivery composition according to claims 36 and 37 wherein the capsules or tablets are coated.
- 39. Use of the solid drug delivery composition according to any one of the claims 1 to 27 for the manufacture of a medicament for treating pain.
  - 40. Use of the solid drug delivery composition according according to any one of the claims 1 to 27 for the manufacture of a medicament for treating inflammation.
- 41. A method for the treatment of pain comprising oral administration to a patient suffering therefrom a solid compound delivery composition according to any one of claims 1 to 27.
  - 42. A method for the treatment of inflammation comprising oral administration to a patient suffering therefrom a solid compound delivery composition according to any one of claims 1 to 27.